e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Mura Marco, Porretta Maria A., Bargagli Elena, Sergiacomi Gianluigi, Zompatori Maurizio, Sverzellati Nicola, Taglieri Amedeo, Mezzasalma Fabrizio, Rottoli Paola, Saltini Cesare, Rogliani Paola
Source:
Eur Respir J 2012; 40: 101-109
Journal Issue:
July
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mura Marco, Porretta Maria A., Bargagli Elena, Sergiacomi Gianluigi, Zompatori Maurizio, Sverzellati Nicola, Taglieri Amedeo, Mezzasalma Fabrizio, Rottoli Paola, Saltini Cesare, Rogliani Paola. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40: 101-109
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 1114-1118
Year: 2002
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Source: Eur Respir Rev 2009; 18: 129-132
Year: 2009
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011
Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Interstitial lung diseases in childhood
Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213
Year: 2002
Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 40: 93-100
Year: 2012
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018
Year: 2019
High short-term mortality following lung biopsy for usual interstitial pneumonia
Source: Eur Respir J 2001; 17: 175-179
Year: 2001
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features
Source: Eur Respir J 2006; 27: 143-150
Year: 2006
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Source: Eur Respir J 2011; 37: 356
Year: 2011
Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years
Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions
Year: 2013
Predictors of survival in idiopathic interstitial pneumonia
Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases
Year: 2007
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
Impact of BAL lymphocytosis > 15% on the prognosis of chronic idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis: a retrospective nationwide study based on multidisciplinary discussion
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Interstitial lung disease
Source: Eur Respir Rev 2013; 22: 26-32
Year: 2013
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept